Amendments to the Claims

1. (Currently amended) A compound represented by the formula (I) or the formula (II):



(I)



(II)

wherein X is



;

ring A is an optionally substituted saturated or unsaturated cyclic hydrocarbon group or saturated or unsaturated heterocyclic group;

ring B is a benzene ring optionally further having one to four substituents;

R_1 is an optionally substituted lower alkyl group, an optionally substituted aryl group, a substituted amido group or an optionally substituted amino group;

each of R_2 to R_4, whether identical or not, is a hydrogen atom, a saturated or unsaturated hydrocarbon group or a saturated or unsaturated heterocyclic group (R_3 and R_4 may bind together to form a ring), except that the compounds shown below are excluded,



or a pharmaceutically acceptable salt thereof.

2. (Currently amended) The compound of claim 1, wherein the compound represented by the formula (I) is a compound represented by the formula (I'):



(I')

wherein ring A' is an optionally substituted saturated or unsaturated heterocyclic group, and R_1 and X~~; the other symbols~~ are as defined in claim 1,

or a pharmaceutically acceptable salt thereof.

3. (Original) The compound of claim 2, wherein in the formula (I'), the ring A' is a saturated or unsaturated cyclic hydrocarbon group or saturated or unsaturated heterocyclic group optionally substituted by at least one substituent selected from the group consisting of saturated or unsaturated cyclic hydrocarbon groups, saturated or unsaturated heterocyclic groups, carboxyl groups, substituted amido groups and optionally substituted lower alkyl groups,

or a pharmaceutically acceptable salt thereof.

4. (Original) The compound of claim 2, wherein in the formula (I'), the ring A' is a saturated or unsaturated heterocyclic group having both any one substituent selected from the group consisting of saturated or unsaturated cyclic hydrocarbon groups and saturated or unsaturated heterocyclic groups, and any one substituent selected from the group consisting of carboxyl groups, substituted amido groups and optionally substituted lower alkyl groups,

or a pharmaceutically acceptable salt thereof.

5. (Original) The compound of claim 1, wherein in the formula (II), the ring formed by mutually binding R_3 and R_4 is a saturated or unsaturated cyclic hydrocarbon group or a saturated or unsaturated heterocyclic group optionally having at least one substituent selected from the group consisting of carboxyl groups, substituted amido groups and optionally substituted lower alkyl groups,

or a pharmaceutically acceptable salt thereof.

6. (Original) The compound of claim 5, wherein in the formula (II), the ring formed by binding of R_3 and R_4 is a saturated or unsaturated cyclic hydrocarbon group optionally having at least one substituent selected from the group consisting of carboxyl groups, substituted amido groups and optionally substituted lower alkyl groups,

or a pharmaceutically acceptable salt thereof.

7. (Original) The compound of claim 6, wherein the saturated or unsaturated cyclic hydrocarbon group is indene,

or a pharmaceutically acceptable salt thereof.

8. (Currently amended) A pharmaceutical composition comprising, as an active ingredient, the compound of ~~any one of claims 1 to 7~~claim 1 or a pharmaceutically acceptable salt thereof.

9. (Currently amended) The pharmaceutical composition of claim 8, ~~which is for the treatment of~~wherein the active ingredient is present in an amount effective to treat a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy.

10. (Original) A pharmaceutical composition comprising, as an active ingredient, a compound that specifically binds to a protein having the amino acid sequence of SEQ ID NO:2.

11. (Currently amended) A pharmaceutical composition comprising, as an active ingredient, a compound that specifically binds to a protein having the amino acid sequence of SEQ ID NO:2, wherein one or more amino acids are deleted, substituted or added, and which;

(i) binds to a compound of formula 1, and

(ii) does not bind to a compound of formula 2



12. (Original) A pharmaceutical composition comprising, as an active ingredient, a compound that specifically binds to a protein having the amino acid sequence of SEQ ID NO:3.

13. (Currently amended) A pharmaceutical composition comprising, as an active ingredient, a compound that specifically binds to a protein having the amino acid sequence of SEQ ID NO:3, wherein one or more amino acids are deleted, substituted or added, and which;

(i) binds to a compound of formula 1, and

(ii) does not bind to a compound of formula 2



14. (Currently amended) The pharmaceutical composition of ~~any one of claims 10 to 13, which is for the treatment of~~claim 10, wherein the active ingredient is present in an amount effective to treat a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy.

15. (Canceled)

16. (Currently amended) A pharmaceutical composition comprising, as an active ingredient, a compound that specifically binds to KH-type splicing regulatory protein (KSRP).

17. (Original) A pharmaceutical composition comprising, as an active ingredient, a compound that regulates the expression of KSRP.

18. (Original) A pharmaceutical composition comprising, as an active ingredient, a compound that regulates the activity of KSRP.

19. (Canceled)

20. (Canceled)

21. (Currently amended) A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an

inflammatory disease and an encephalopathy, which method comprises: ~~the steps shown below;~~

(1) ~~a step of~~ bringing KSRP or a functional fragment thereof into contact with a ~~test~~ compound,

(2) ~~a step of~~ determining whether or not the ~~test~~ compound specifically binds to KSRP or a functional fragment thereof, and

(3) ~~a step of~~ selecting a ~~test~~ compound that specifically binds to KSRP or a functional fragment thereof ~~in the step (2) above~~.

22. (Currently amended) A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises: ~~the steps shown below;~~

(1) ~~a step of~~ bringing a protein having the amino acid sequence of SEQ ID NO:2 or a functional fragment thereof into contact with a ~~test~~ compound,

(2) ~~a step of~~ determining whether or not the ~~test~~ compound specifically binds to the protein or a functional fragment thereof, and

(3) ~~a step of~~ selecting a ~~test~~ compound that specifically binds to the protein or a functional fragment thereof ~~in the step (2) above~~.

23. (Currently amended) A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises: ~~the steps shown below;~~

(1) ~~a step of~~ bringing a protein having the amino acid sequence of SEQ ID NO:2, wherein one or more amino acids are deleted, substituted or added, and which:

(i) binds to a compound of formula 1, and

(ii) does not bind to a compound of formula 2



or a functional fragment thereof into contact with a ~~test~~ compound,

(2) ~~a step of~~ determining whether or not the ~~test~~ compound specifically binds to the protein or a functional fragment thereof, and

(3) ~~a step of~~ selecting a ~~test~~ compound that specifically binds to the protein or a functional fragment thereof ~~in the step (2) above~~.

24. (Currently amended) A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises: ~~the steps shown below;~~

(1) ~~a step of~~ bringing a protein having the amino acid sequence of SEQ ID NO:3 or a functional fragment thereof into contact with a ~~test~~ compound,

(2) ~~a step of~~ determining whether or not the ~~test~~ compound specifically binds to the protein or a functional fragment thereof, and

(3) ~~a step of~~ selecting a ~~test~~ compound that specifically binds to the protein or a functional fragment thereof ~~in the step (2) above~~.

25. (Currently amended) A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises: ~~the steps shown below;~~

(1) ~~a step of~~ bringing a protein having the amino acid sequence of SEQ ID NO:3, wherein one or more amino acids are deleted, substituted or added, and which:

(i) binds to a compound of formula 1, and

(ii) does not bind to a compound of formula 2



or a functional fragment thereof into contact with a ~~test~~ compound,

(2) ~~a step of~~ determining whether or not the ~~test~~ compound specifically binds to the protein or a functional fragment thereof, and

(3) ~~a step of~~ selecting a ~~test~~ compound that specifically binds to the protein or a functional fragment thereof ~~in the step (2) above~~.

26. (Currently amended) A compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, obtained by the screening method of ~~any one of claims 21 to 25~~claim 21.

27. (New) The pharmaceutical composition of claim 11, wherein the active ingredient is present in an amount effective to treat a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy.

28. (New) The pharmaceutical composition of claim 12, wherein the active ingredient is present in an amount effective to treat a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy.

29. (New) The pharmaceutical composition of claim 13, wherein the active ingredient is present in an amount effective to treat a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy.

30. (New) A compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, obtained by the screening method of claim 22.

31. (New) A compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, obtained by the screening method of claim 23.

32. (New) A compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, obtained by the screening method of claim 24.

33. (New) A compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, obtained by the screening method of claim 25.